ID   T47D-KBluc
AC   CVCL_K229
SY   T47D-KBLUC; T47D Kbluc; T47D_KBluc; T47DKBluc; T47DKBLUC
DR   CLO; CLO_0037191
DR   ATCC; CRL-2865
DR   cancercelllines; CVCL_K229
DR   GEO; GSM1172905
DR   GEO; GSM1173001
DR   LINCS_HMS; 51091
DR   Wikidata; Q54971561
RX   PubMed=15166400;
RX   PubMed=24176112;
RX   PubMed=25960936;
CC   Part of: JWGray breast cancer cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Used to screen chemicals for estrogenic or anti-estrogenic activity. Selected for responsiveness to 17-beta-estradiol. Transfected with a pGL2.TATA.Inr.luc.neo plasmid which contains three estrogen responsive elements upstream of the luciferase reporter gene (PubMed=15166400).
CC   Doubling time: 70.61 hours (JWGray panel).
CC   HLA typing: A*33:01,33:01; B*14:02,14:02; C*08:02,08:02; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-2865
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 10
ST   D18S51: 17
ST   D19S433: 14
ST   D21S11: 28,31
ST   D2S1338: 24
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 23
ST   Penta D: 10,12
ST   Penta E: 7,14
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 14
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0553 ! T-47D
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 02-05-24; Version: 23
RX   PubMed=15166400; DOI=10.1093/toxsci/kfh180;
RA   Wilson V.S., Bobseine K., Gray L.E. Jr.;
RT   "Development and characterization of a cell line that stably expresses
RT   an estrogen-responsive luciferase reporter for the detection of
RT   estrogen receptor agonist and antagonists.";
RL   Toxicol. Sci. 81:69-77(2004).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).